Human Rabies Immunoglobulin Bio Products Laboratory (Human Rabies Immunoglobulin)

Human Rabies Immunoglobulin is indicated for passive immunization in individuals who have potentially been exposed to rabies virus.

• Immediate provision of rabies‑neutralizing antibodies after a bite or scratch from a suspected rabid animal.
• Use in conjunction with active rabies vaccination as part of a complete post‑exposure prophylaxis regimen.
• Administration when the wound is severe, deep, or located near the central nervous system.
• Use for patients who cannot receive the vaccine due to contraindications, as a temporary protective measure.
• Application in cases where the timing of vaccine initiation is delayed.

• Human rabies immunoglobulin consists of purified polyclonal IgG antibodies derived from pooled human plasma that have high affinity for the rabies virus glycoprotein. After intramuscular or infiltrative administration, the antibodies circulate systemically and bind to viral particles at the site of inoculation, preventing attachment to neuronal receptors and blocking retrograde transport along peripheral nerves. This passive neutralization provides immediate protection until active immunity from vaccination develops.

Adverse reactions to human rabies immunoglobulin are generally infrequent but can vary in severity, ranging from mild local discomfort to rare systemic events that require medical attention.

Common

• Injection site pain, redness, or swelling.
• Mild fever or chills.
• Headache or fatigue.
• Nausea or gastrointestinal discomfort.
• Localized itching or rash at the injection site.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing, hives, or hypotension.
• Serum sickness–like illness presenting with fever, rash, arthralgia.
• Neurological symptoms such as peripheral neuropathy or aseptic meningitis.
• Renal impairment or acute kidney injury.
• Coagulation abnormalities (e.g., thrombocytopenia).

Human rabies immunoglobulin should be administered with consideration of specific precautions to ensure safety and optimal efficacy.

• Verify the product’s expiration date and integrity before use.
• Assess the patient for known hypersensitivity to human immunoglobulins or blood‑derived products.
• Avoid intravascular injection; administer only by the recommended intramuscular or wound‑infiltration routes.
• Observe the patient for at least 30 minutes after administration for signs of an allergic reaction.
• Do not exceed the recommended volume at a single injection site to prevent tissue necrosis.
• Document the lot number and batch information for traceability.

When co‑administered with other agents, human rabies immunoglobulin may interact in ways that affect safety or efficacy, requiring attention to specific drug combinations.

Avoid

• Live attenuated vaccines administered concurrently, as passive antibodies can diminish the vaccine’s immunogenic response.
• High‑dose intravenous immunoglobulin products, which may increase the risk of hyperviscosity or renal complications.

Use with caution

• Anticoagulants or antiplatelet agents, because injection‑site bleeding may be prolonged.
• Monoclonic antibodies targeting immune pathways, which could alter the clearance of the immunoglobulin.
• Renal‑impairing medications, as the combined protein load may stress kidney function.
• Vaccines requiring a strong cellular response (e.g., hepatitis B), as passive antibodies may interfere with antigen presentation.